Peptide Manufacturing Enters the Industrial Era

Key Takeaways

• GLP-1 demand has transformed peptide manufacturing from a specialized capability into a strategic capacity challenge requiring larger-scale synthesis, purification, lyophilization, and supply-chain planning.

• Peptide API manufacturing depends on more than solid-phase peptide synthesis capacity; bottlenecks can emerge in raw materials, purification, freeze-drying, analytical release, fill-finish, and distribution.

• High solvent and reagent use makes peptide manufacturing both an environmental and economic challenge, linking sustainability directly to cost, throughput, waste handling, and facility utilization.

• CDMOs are becoming strategic partners in peptide development as sponsors seek expertise in process development, scale-up, impurity control, quality systems, and long-term supply security.

• Recent investments by peptide manufacturers and pharmaceutical companies show that industrial-scale peptide capacity is becoming a critical enabler of future therapeutic growth.

The resurgence of peptide therapeutics is often described through the lens of molecular design, clinical success, and expanding therapeutic relevance. Those forces are real, but they tell only part of the story. As peptide drugs become more complex, more widely used, and more commercially important, the field is also confronting a parallel manufacturing challenge. The next phase of peptide innovation will depend on whether improved molecules can be made, purified, supplied, and delivered at the scale required by modern medicine.

Glucagon-like peptide-1 (GLP-1) therapies have made that challenge especially visible. Historically, many peptide active pharmaceutical ingredients (APIs) were produced at kilogram scale. With GLP-1 demand, production requirements are increasingly measured in multi-kilogram quantities and, in some cases, metric tons.¹ That shift changes the nature of peptide manufacturing. A process suited to specialized or lower-volume indications may not be sufficient when a peptide medicine is intended for large chronic patient populations.

The scale-up challenge extends beyond synthesis. High-demand peptide products place pressure on raw-material supply, solid-phase peptide synthesis (SPPS) capacity, purification infrastructure, lyophilization, analytical release, fill-finish, and finished-product distribution. For GLP-1 medicines, those pressures are intensified by the combination of large patient populations, chronic use, structural complexity, and the need for consistent global supply.

This makes the peptide renaissance a capacity and supply chain story as much as a therapeutic one. The industry is no longer asking only how to design peptides with better potency, stability, half-life, or delivery profiles. It must also determine how to industrialize those advances in ways that are reliable, sustainable, cost-effective, and compatible with current good manufacturing practice (cGMP) expectations.

Scaling peptide manufacturing requires more than increasing batch size. Peptides are chemically synthesized molecules, but they do not behave like conventional small molecules with slightly longer structures. Their production often involves repeated chemical steps, specialized raw materials, careful impurity control, and downstream operations that become more demanding as sequence length and molecular complexity increase.

SPPS has helped streamline peptide production and expand the clinical development pipeline.² Its core advantage is that peptide chains can be assembled in a controlled stepwise fashion. In SPPS, deprotection and coupling are repeated for each amino acid addition, allowing the desired sequence to be built one residue at a time.³ That repeatability makes the platform powerful, but it also creates manufacturing vulnerabilities. Small inefficiencies at each step can accumulate across a long sequence, affecting yield, impurity formation, cycle time, and downstream purification burden.

Those considerations become more pronounced as peptides become longer or more structurally modified. Each coupling step must perform reliably, and each protecting-group strategy, resin choice, solvent system, and washing step can influence the final product profile. If incomplete reactions or side products accumulate, purification becomes more difficult and costly. Added features, such as lipidation, non-natural amino acids, or other structural changes, may improve the therapeutic profile, but they can also create new process development challenges.

Industrial peptide manufacturing also extends well beyond synthesis. A full peptide manufacturing workflow includes synthesis, purification, product isolation, raw-material procurement, primary packaging, quality control, and quality assurance.³ A process suitable for early clinical supply may need substantial refinement before it can support late-stage trials or commercial volumes, especially if demand is expected to grow quickly.

That is why peptide scale-up must be approached as an integrated process rather than a simple chemistry transfer. Chemistry decisions affect purification, raw-material choices influence impurity and supply risk, and isolation strategies shape product handling and stability. As peptide therapeutics move into larger commercial opportunities, connecting these elements becomes central to manufacturing success.

GLP-1 therapies have changed the scale assumptions around peptide manufacturing. For years, many peptide products fit a more specialized manufacturing model, often serving narrower indications or lower-volume markets. The rapid growth of GLP-1 medicines for diabetes and obesity has altered that context. GLP-1 use in those large patient populations is now one of the most important growth drivers for the peptide market, although it is not the only factor supporting broader peptide demand.⁴

That shift matters because high-volume chronic therapies create a very different manufacturing profile than smaller specialty programs. Peptide API demand that was historically often measured at kilogram scale is now increasingly measured in multi-kilogram quantities and, in some cases, metric tons for GLP-1 products.¹ This increase affects how much SPPS capacity is needed, how purification systems are scheduled and sized, how much lyophilization capacity is available, and how far in advance commercial campaigns must be planned.

The supply experience with GLP-1s also shows why demand should be viewed across the full supply ecosystem, not only API output. The FDA determined that the semaglutide injection shortage was resolved in February 2025, but it also noted that localized supply disruptions may still occur as products move through the supply chain.⁵ A formal shortage resolution does not necessarily mean patients and prescribers will experience supply uniformly across every region or channel.

GLP-1s have therefore become a stress test for peptide manufacturing. They show how quickly a successful peptide modality can move from technical achievement to industrial challenge. Large chronic-use populations require reliability over time, not simply successful batches. For the broader peptide field, the lesson is clear: manufacturing strategy must anticipate success rather than react to it, particularly when a product has the potential to move beyond a niche therapeutic market.

Peptide manufacturing capacity is often discussed in terms of synthesis scale, but reactor volume is only one part of the equation. For high-demand GLP-1 programs, several capabilities must work together: large-capacity SPPS reactors, scalable purification infrastructure, sufficient freeze-drying capacity, and reliable raw-material supply chains. If one element cannot keep pace, the entire manufacturing train can become constrained.

That is especially important for long and chemically modified peptides. GLP-1 peptides can require many coupling cycles, and additional structural features, including fatty-acid side chains or other modifications, can complicate both synthesis and purification.¹ These modifications may be essential to the drug’s clinical profile, including longer exposure or improved dosing convenience, but they can also increase the burden on process development. A feature that improves pharmacology may introduce new impurity risks, increase purification complexity, reduce yield, or lengthen the manufacturing campaign.

Downstream operations can become just as limiting as synthesis. When GLP-1 programs require repeated large-scale campaigns, reactors, purification columns, and lyophilizers can all become bottlenecks. Purification throughput may limit how quickly crude peptide can be processed. Freeze-drying capacity may affect how efficiently purified material can be isolated and stabilized. Analytical release and quality control can also influence timing, particularly when programs require tight impurity control and consistent product characterization across campaigns.

These constraints are interdependent. A faster synthesis step may create little practical benefit if purification cannot absorb the additional crude material. Expanded purification capacity may not solve the problem if lyophilization is fully utilized. Additional equipment may still fall short if protected amino acids, resins, solvents, fatty-acid side chains, or other modifiers cannot be sourced reliably at the required quality and volume. Campaign scheduling becomes a strategic exercise in balancing upstream output, downstream throughput, raw-material availability, and quality release.

Headline reactor volume is an incomplete measure of peptide capacity. The more important question is whether the process can move consistently through synthesis, purification, isolation, testing, and release without shifting the bottleneck downstream.

Peptide scale-up depends on reliable access to specialized inputs that must be available at the right quality, quantity, and timing. For high-demand GLP-1 manufacturing, critical raw-material categories include protected amino acids, solid-phase resins, solvents, fatty-acid side chains, and other modifiers.¹ These inputs are not interchangeable commodities in a simple sense. Their quality, availability, and suitability for a given process can influence yield, impurity profiles, purification burden, and campaign timing.

As peptide demand increases, raw-material planning becomes part of process development rather than a late procurement exercise. A synthesis route may be scientifically sound, but it still depends on a supply base that can support repeated campaigns at the required scale. This is especially important for modified peptides, where specialized side chains, protecting groups, resins, or other components may create additional sourcing complexity.

Recent industry investments reflect that shift. Bachem reported increased production of starting material in Vionnaz as part of its effort to secure supply chain.⁴ Lilly has similarly framed its Alabama API facility as part of a broader strategy to support domestic API production and strengthen supply-chain resilience.⁶ These examples point to a larger trend: companies are treating control over key manufacturing inputs and regional production capacity as part of the value chain for peptide medicines.

Supply chain resilience also extends beyond peptide API production. Novo Nordisk reported acquiring three former Catalent fill-finish sites in 2024 to expand manufacturing capacity, increase future optionality, and improve supply-network flexibility.⁷ That move illustrates how peptide supply can depend on downstream capacity as much as upstream synthesis.

For pharma companies and manufacturing partners, supply chain strategy should be integrated into technical development alongside route selection, process optimization, impurity control, and scale-up planning. As peptide programs move toward larger patient populations, supply reliability will depend on a coordinated view of raw materials, API capacity, downstream operations, and regional manufacturing flexibility.

The economics of peptide manufacturing differ from those of many other therapeutic modalities because the work is capital intensive, technically specialized, and highly sensitive to process performance across multiple steps. Important financial considerations in peptide manufacturing include high capital expenditures for facilities and equipment, multiple process steps, long campaign duration, and high operating expenditures.³ Those factors make scale-up an economic challenge as much as a technical one.

At the process level, cost is shaped by many interconnected variables. Sequence length, coupling efficiency, resin use, solvent consumption, cycle time, purification load, isolation strategy, analytical requirements, and batch scheduling can all affect the economics of a peptide program. Small yield losses can become more consequential as campaigns scale, especially for longer or modified peptides that require many synthesis steps and extensive purification. Equipment utilization also matters. A process that ties up reactors, purification systems, or lyophilizers for extended periods can limit facility flexibility and increase the opportunity cost of each campaign.

These dynamics help explain why peptide manufacturing capacity cannot be created quickly or casually. Facilities must be designed or adapted for specialized synthesis, solvent handling, purification, isolation, and quality control requirements. Investments in equipment and infrastructure may be large, and they are not always easily repurposed for other product classes.

These economics also contribute to high barriers to entry and high customer switching costs in peptide CDMO manufacturing, where specialized expertise, quality expectations, security-of-supply requirements, capital intensity, and track record all matter. For pharma companies, partner selection is therefore not simply a question of finding available capacity at the next development milestone. It requires confidence that the process can be optimized, scaled, controlled, and supported over the product’s life cycle.

Sustainability in peptide manufacturing is often framed as an environmental concern, but it is also an economic and capacity issue. Peptide synthesis is associated with comparatively high volumes of hazardous solvents and reagents, making material use a central challenge for both environmental performance and manufacturing efficiency.⁸ As peptide demand rises, especially for high-volume products, those material requirements affect procurement, storage, waste handling, solvent recovery, facility design, operator safety, campaign cost, and throughput.

Process mass intensity (PMI) is one useful way to understand this burden. PMI measures the mass of materials used to produce a given mass of product, helping manufacturers benchmark material efficiency and identify where a process may be driving cost, environmental impact, safety concerns, and health-related risks.⁹ In an assessment of 40 synthetic peptide processes, SPPS had an approximate PMI of 13,000, with lower values reported for small molecules and biopharmaceuticals.¹⁰ That comparison highlights why peptide manufacturing can carry such a large material footprint.

The implications are practical. High solvent and reagent use can increase operating expense, complicate waste management, and place additional demands on facility infrastructure. It can also affect production scheduling if solvent handling, cleaning, waste disposal, or environmental controls become limiting factors. For manufacturers trying to support repeated large-scale peptide campaigns, material intensity becomes part of the capacity equation.

Chemical API production creates both economic and ecological challenges because of the large amounts of starting materials and solvents required.⁴ For peptide developers and manufacturing partners, that makes greener chemistry a manufacturing-performance issue: processes that use materials more efficiently can lower operational burden, improve facility utilization, and support more sustainable scale-up.

Greener peptide manufacturing cannot be reduced to replacing one solvent with another. Each change must preserve process performance, product quality, and compatibility with cGMP expectations. Because peptide synthesis relies on repeated reaction cycles, even small changes to solvent systems, resins, reagents, or washing steps can affect yield, impurity formation, purification burden, and scalability.

Alternative solvents are a useful example. Research into greener peptide chemistry has examined solvent substitution and resin compatibility, but solvent selection is constrained by many interacting factors. Candidate solvents can differ in resin swelling, amino acid and reagent solubility, viscosity, stability, toxicity, biodegradability, and broader sustainability scores.¹¹ A solvent that looks attractive from an environmental perspective may perform poorly in coupling reactions, create handling challenges, affect impurity formation, or fail to support the resin behavior required for efficient SPPS.

Those tradeoffs matter because peptide manufacturing depends on consistency across many repeated steps. If a greener solvent slows reactions, reduces coupling efficiency, increases side products, or complicates washing and purification, the overall process may become less efficient despite the environmental intent. Similarly, a change that works at small scale may not translate cleanly into larger campaigns, where mixing, heat transfer, solvent recovery, equipment compatibility, and waste streams become more important.

Near-term progress may come from a combination of process improvements rather than a single platform shift. Green chemistry, process intensification, automation, and industrial-scale optimization are all strategies in play to increase throughput, improve sustainability, and accelerate development timelines. This combination points to a practical direction for the field: greener peptide manufacturing will likely advance through coordinated, process-specific improvements that reduce waste and complexity without compromising quality, robustness, scalability, or supply reliability.

As peptide programs become more complex and demand expectations rise, contract development and manufacturing organizations (CDMOs) are becoming more than sources of reactor volume. Sponsors need partners that can help develop, scale, control, and sustain a process over the full product life cycle.

That shift reflects the technical demands of peptide manufacturing. Peptide production requires experience with route and process development, SPPS, purification, impurity control, raw-material qualification, analytical strategy, quality systems, and regulatory expectations. For modified or high-volume peptides, those capabilities become especially important because early process decisions can affect cost, yield, scalability, and supply reliability later.

Quality infrastructure is also central to the CDMO role. Manufacturing credibility is not established only by technical know-how. It also depends on inspection readiness, documentation discipline, quality assurance, data integrity, and the ability to maintain consistent process control across development and commercial supply. For peptide programs moving toward later-stage or commercial production, those systems can be as important as synthesis capacity itself.

The strategic nature of these partnerships is reinforced by the difficulty of changing course once a program advances. Peptide CDMO manufacturing has high barriers to entry and high customer switching costs, reflecting specialized technical expertise, quality and reliability expectations, security-of-supply requirements, capital intensity, and the importance of an established track record. A process transferred to a new partner may require technical redevelopment, method transfer, comparability work, additional validation, new regulatory documentation, and supply-chain adjustments. For late-stage or commercial programs, those risks can affect both timelines and continuity of supply.

That reality makes CDMO selection an early strategic decision. Sponsors need partners that can support the molecule they have today and the product it may become if clinical and commercial demand grows. In peptide development, the manufacturing partner can shape technical feasibility, process efficiency, raw-material planning, future capacity alignment, and long-term supply security.

Market forecasts can help frame the scale of opportunity in peptide therapeutics, but they are not the strongest evidence of the manufacturing shift underway. Estimates vary depending on how the market is defined, which products are included, and how future demand is modeled. A clearer signal comes from the capital now moving into specialized peptide manufacturing capacity. Across CDMOs and pharmaceutical manufacturers, companies are investing in SPPS, downstream processing, starting-material production, and commercial-scale infrastructure designed to support larger and more complex peptide programs.

PolyPeptide provides one example of this shift. The company invested around EUR 100 million over three years to support a multi-year commercial GLP-1 agreement and began production at large-scale SPPS capacity in Braine-l’Alleud, Belgium, in late 2024.¹² It also finalized debottlenecking of upstream and downstream capacity in Torrance, advanced work to double SPPS capacity in Strasbourg, and launched work to double SPPS capacity in Malmö.

Bachem has reported a similar pattern of investment across its network. The company added capacity in Bubendorf, expanded medium and larger production capacity in Vista, and increased starting-material production in Vionnaz to secure supply chain.⁴ These examples reflect the multi-layered nature of peptide capacity. Expanding synthesis alone is not sufficient if starting materials, purification, downstream operations, and supply-chain controls cannot keep pace.

CordenPharma has also announced major peptide manufacturing expansion. The company announced a more than EUR 500 million facility in Muttenz, Switzerland, with multiple manufacturing lines designed for small-, medium-, and large-scale peptide production.¹³ That Switzerland expansion is planned to include more than 5,000 liters of SPPS reactor capacity, with construction and qualification expected from 2025 through 2027 and commercial activities planned for the first half of 2028. In parallel, CordenPharma reported Colorado peptide-capacity expansions expected to add 25,000 liters of SPPS capacity and bring total reactor capacity there to more than 42,000 liters by 2028.

These examples also show why peptide capacity cannot be turned on immediately in response to demand. New lines must be designed, built, equipped, qualified, staffed, validated, and integrated into quality systems before they can support commercial supply. That long lead time makes current investment one of the clearest signals that peptide manufacturing has become a strategic priority.

For injectable peptide medicines, API capacity is necessary but not sufficient. A manufacturer may be able to synthesize and purify more peptide API, but patients ultimately depend on a broader supply chain that includes fill-finish capacity, device or presentation components, packaging, quality release, inventory movement, and distribution. As GLP-1 demand has demonstrated, pressure at any one of those points can affect how reliably finished medicines reach patients.

This is why recent investments have extended beyond peptide synthesis itself. Novo Nordisk’s acquisition of three former Catalent fill-finish sites in 2024 to expand manufacturing capacity, increase future optionality, and strengthen supply-network flexibility reflects the importance of downstream capacity in high-demand injectable products.⁷ Even when API supply improves, finished-dose production must be able to keep pace with commercial demand, regional distribution needs, and product-presentation requirements.

Lilly has also announced additional manufacturing investments related to Zepbound and Mounjaro production.¹⁴ These investments point to the same broader reality: scaling successful peptide medicines requires coordinated capacity across multiple parts of the value chain. For products used by large patient populations, manufacturers must plan not only for API campaigns but also for filling lines, device supply, packaging formats, release testing, storage requirements where applicable, and distribution logistics.

The FDA’s GLP-1 shortage update underscores this distinction. Even after the agency determined that the semaglutide injection shortage had been resolved, it noted that localized supply disruptions may still occur as products move through the supply chain.⁵ That caveat separates formal national shortage status from the practical experience of supply at the regional, pharmacy, prescriber, or patient level.

For drug developers and manufacturing partners, peptide scale-up must therefore be planned from raw materials through finished product. Supply resilience depends less on any single manufacturing node than on the strength of the full network that carries the product to patients.

The peptide renaissance began with better science, but its next phase will depend on industrial execution. Advances in peptide design, stabilization, delivery, and therapeutic targeting have expanded what the modality can do. GLP-1 drugs have shown that peptide medicines can reach large chronic disease populations and reshape commercial expectations. That success has also made the manufacturing challenge impossible to separate from the therapeutic opportunity.

For the field to keep advancing, peptide manufacturing must become more scalable, more efficient, and more resilient. That will require industrialized synthesis platforms, robust purification strategies, reliable access to specialized raw materials, sufficient downstream capacity, and CDMO partnerships capable of supporting both complex development programs and large-scale commercial demand. It will also require greater attention to PMI, solvent and reagent burden, waste handling, automation, and process intensification, because sustainability and manufacturing economics are increasingly linked.

The broader lesson from the GLP-1 era is that success must be anticipated. Peptide programs with strong clinical potential can move quickly from specialized development assets to high-demand products, and manufacturing networks must be prepared for that possibility. The next question for peptide therapeutics is therefore not only how precisely they can be designed. It is how reliably, sustainably, and globally they can be made.

1. “GLP-1 Demand: What it means for peptide manufacturers.” Bachem Knowledge Center. 20 Ap. 2026.

2. Al Musaimi, Othman, et al. “2024 FDA TIDES (Peptides and Oligonucleotides) Harvest.” Pharmaceuticals. 18: 291 (2025).

3. “Innovation for large-scale peptide production.” PolyPeptide Group. 6 Dec. 2024.

4. Bachem Annual Report 2024. Bachem. 2025.

5. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. U.S. Food and Drug Administration. 1 Apr. 2026.

6. Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama. Eli Lilly and Company. 9 Dec. 2025.

7. Annual Report 2024. Novo Nordisk. 5 Feb. 2025.

8. “Peptides.” ACS Green Chemistry Institute Pharmaceutical Roundtable. Accessed 12 May 2026.

9. “Process Mass Intensity Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis.” ACS Green Chemistry Institute Pharmaceutical Roundtable. Accessed 12 May 2026.

10. Kekessie, Ivy, et al. “Process Mass Intensity (PMI): A Holistic Analysis of Current Peptide Manufacturing Processes Informs Sustainability in Peptide Synthesis.” The Journal of Organic Chemistry. 89: 4261–4282 (2024).

11. Ferrazzano, Lucia, et al. “Sustainability in peptide chemistry: current synthesis and purification technologies and future challenges.” Green Chemistry. 24: 975–1020 (2022).

12. “Business review.” Annual Report 2024. PolyPeptide Group AG. 10 Mar. 2025.

13. CordenPharma Expands Peptide Platform with more than 500 Million Euro Greenfield Facility Construction in the Basel Region of Switzerland. CordenPharma. 5 Mar. 2025.

14. Lilly commits additional $4.5 billion across Indiana manufacturing sites; opens first dedicated genetic medicine facility. Eli Lilly and Company. 6 May 2026.